Browse by pharmacologic class
996 established pharmacologic classes, mechanisms of action, chemical structures and physiologic effects. These labels come from the FDA's established pharmacologic class vocabulary and appear on the drug labelling itself.
330 of 996 have their own browse page. The remainder cover fewer than 10 products and are best reached from the product pages themselves.
| Class | Medications | |
|---|---|---|
| Anti-Inflammatory Agents · EPC | 251 | Browse → |
| Cyclooxygenase Inhibitors · MoA | 251 | Browse → |
| Non-Steroidal · CS | 251 | Browse → |
| Nonsteroidal Anti-inflammatory Drug · EPC | 251 | Browse → |
| Corticosteroid Hormone Receptor Agonists · MoA | 215 | Browse → |
| Corticosteroid · EPC | 215 | Browse → |
| Histamine H1 Receptor Antagonists · MoA | 136 | Browse → |
| Histamine-1 Receptor Antagonist · EPC | 134 | Browse → |
| Cytochrome P450 3A4 Inhibitors · MoA | 118 | Browse → |
| Decreased Central Nervous System Disorganized Electrical Activity · PE | 114 | Browse → |
| Opioid Agonist · EPC | 109 | Browse → |
| Osmotic Activity · MoA | 105 | Browse → |
| P-Glycoprotein Inhibitors · MoA | 105 | Browse → |
| Osmotic Laxative · EPC | 103 | Browse → |
| Central Nervous System Stimulation · PE | 95 | Browse → |
| Central Nervous System Stimulant · EPC | 93 | Browse → |
| Cytochrome P450 2C19 Inhibitors · MoA | 93 | Browse → |
| Cytochrome P450 3A Inhibitors · MoA | 89 | Browse → |
| Kinase Inhibitor · EPC | 89 | Browse → |
| Adrenergic alpha-Agonists · MoA | 85 | Browse → |
| alpha-Adrenergic Agonist · EPC | 85 | Browse → |
| Increased Large Intestinal Motility · PE | 83 | Browse → |
| Inhibition Large Intestine Fluid/Electrolyte Absorption · PE | 83 | Browse → |
| Calcium Channel Antagonists · MoA | 75 | Browse → |
| Full Opioid Agonists · MoA | 74 | Browse → |
| Proton Pump Inhibitor · EPC | 74 | Browse → |
| Proton Pump Inhibitors · MoA | 74 | Browse → |
| Serotonin Uptake Inhibitors · MoA | 73 | Browse → |
| Adrenergic beta-Antagonists · MoA | 72 | Browse → |
| Cytochrome P450 2D6 Inhibitors · MoA | 72 | Browse → |
| beta-Adrenergic Blocker · EPC | 72 | Browse → |
| Angiotensin 2 Receptor Blocker · EPC | 67 | Browse → |
| Aminoglycoside Antibacterial · EPC | 66 | Browse → |
| Aminoglycosides · CS | 66 | Browse → |
| Angiotensin 2 Receptor Antagonists · MoA | 63 | Browse → |
| Anti-epileptic Agent · EPC | 62 | Browse → |
| Atypical Antipsychotic · EPC | 62 | Browse → |
| Cholinergic Nicotinic Agonist · EPC | 61 | Browse → |
| Nicotine · CS | 61 | Browse → |
| Increased Diuresis · PE | 59 | Browse → |
| Cytochrome P450 2C8 Inhibitors · MoA | 56 | Browse → |
| Calcium Channel Blocker · EPC | 55 | Browse → |
| Polymyxin-class Antibacterial · EPC | 55 | Browse → |
| Polymyxins · CS | 55 | Browse → |
| Cytochrome P450 3A4 Inducers · MoA | 54 | Browse → |
| Decreased Prostaglandin Production · PE | 54 | Browse → |
| Local Anesthesia · PE | 53 | Browse → |
| Stimulation Large Intestine Fluid/Electrolyte Secretion · PE | 53 | Browse → |
| Decreased Respiratory Secretion Viscosity · PE | 52 | Browse → |
| Serotonin Reuptake Inhibitor · EPC | 51 | Browse → |
| Dihydropyridine Calcium Channel Blocker · EPC | 49 | Browse → |
| Dihydropyridines · CS | 49 | Browse → |
| Potassium Compounds · CS | 49 | Browse → |
| Potassium Salt · EPC | 49 | Browse → |
| Antiarrhythmic · EPC | 48 | Browse → |
| Benzodiazepine · EPC | 48 | Browse → |
| Benzodiazepines · CS | 48 | Browse → |
| Expectorant · EPC | 48 | Browse → |
| Histamine H2 Receptor Antagonists · MoA | 48 | Browse → |
| Histamine-2 Receptor Antagonist · EPC | 48 | Browse → |
| Increased Respiratory Secretions · PE | 48 | Browse → |
| Amide Local Anesthetic · EPC | 47 | Browse → |
| Amides · CS | 47 | Browse → |
| Biguanide · EPC | 47 | Browse → |
| Biguanides · CS | 47 | Browse → |
| Thiazide Diuretic · EPC | 47 | Browse → |
| Thiazides · CS | 47 | Browse → |
| Cytochrome P450 2C9 Inducers · MoA | 46 | Browse → |
| Estrogen Receptor Agonists · MoA | 45 | Browse → |
| Estrogen · EPC | 45 | Browse → |
| Adrenergic alpha2-Agonists · MoA | 44 | Browse → |
| Azole Antifungal · EPC | 44 | Browse → |
| Azoles · CS | 44 | Browse → |
| Breast Cancer Resistance Protein Inhibitors · MoA | 44 | Browse → |
| Central alpha-2 Adrenergic Agonist · EPC | 44 | Browse → |
| Cytochrome P450 2B6 Inducers · MoA | 44 | Browse → |
| Norepinephrine Uptake Inhibitors · MoA | 44 | Browse → |
| Sigma-1 Agonist · EPC | 44 | Browse → |
| Sigma-1 Receptor Agonists · MoA | 44 | Browse → |
| Uncompetitive N-methyl-D-aspartate Receptor Antagonist · EPC | 44 | Browse → |
| Uncompetitive NMDA Receptor Antagonists · MoA | 44 | Browse → |
| Phosphate Binder · EPC | 42 | Browse → |
| Phosphate Chelating Activity · MoA | 42 | Browse → |
| Anticholinergic · EPC | 41 | Browse → |
| Catecholamines · CS | 41 | Browse → |
| Cephalosporin Antibacterial · EPC | 41 | Browse → |
| Cephalosporins · CS | 41 | Browse → |
| Cholinergic Antagonists · MoA | 41 | Browse → |
| Decreased Cell Wall Synthesis & Repair · PE | 41 | Browse → |
| Mood Stabilizer · EPC | 41 | Browse → |
| Protein Kinase Inhibitors · MoA | 41 | Browse → |
| Progesterone Congeners · CS | 40 | Browse → |
| Progestin · EPC | 40 | Browse → |
| Catecholamine · EPC | 39 | Browse → |
| Decreased Platelet Aggregation · PE | 39 | Browse → |
| Penicillin-class Antibacterial · EPC | 38 | Browse → |
| Penicillins · CS | 38 | Browse → |
| Adrenergic beta-Agonists · MoA | 37 | Browse → |
| Adrenergic beta2-Agonists · MoA | 37 | Browse → |
| Cytochrome P450 2C19 Inducers · MoA | 37 | Browse → |
| Cytochrome P450 3A Inducers · MoA | 37 | Browse → |
| Decreased Sebaceous Gland Activity · PE | 37 | Browse → |
| beta-Adrenergic Agonist · EPC | 37 | Browse → |
| beta2-Adrenergic Agonist · EPC | 37 | Browse → |
| Opioid Agonists · MoA | 35 | Browse → |
| Phenothiazine · EPC | 35 | Browse → |
| Phenothiazines · CS | 35 | Browse → |
| Retinoid · EPC | 35 | Browse → |
| Retinoids · CS | 35 | Browse → |
| Angiotensin Converting Enzyme Inhibitor · EPC | 34 | Browse → |
| Angiotensin-converting Enzyme Inhibitors · MoA | 34 | Browse → |
| Cytochrome P450 2C9 Inhibitors · MoA | 34 | Browse → |
| Nucleoside Analog · EPC | 34 | Browse → |
| Serotonin 1b Receptor Agonists · MoA | 34 | Browse → |
| Serotonin 1d Receptor Agonists · MoA | 34 | Browse → |
| Serotonin-1b and Serotonin-1d Receptor Agonist · EPC | 34 | Browse → |
| Calculi Dissolution Agent · EPC | 33 | Browse → |
| Cholinergic Muscarinic Antagonist · EPC | 33 | Browse → |
| Cholinergic Muscarinic Antagonists · MoA | 33 | Browse → |
| HMG-CoA Reductase Inhibitor · EPC | 33 | Browse → |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors · MoA | 33 | Browse → |
| Macrolides · CS | 32 | Browse → |
| Organic Cation Transporter 2 Inhibitors · MoA | 32 | Browse → |
| Cytochrome P450 1A2 Inhibitors · MoA | 31 | Browse → |
| Macrolide Antimicrobial · EPC | 31 | Browse → |
| Vasodilation · PE | 31 | Browse → |
| Estradiol Congeners · CS | 30 | Browse → |
| Inhibition Small Intestine Fluid/Electrolyte Absorption · PE | 30 | Browse → |
| Magnesium Ion Exchange Activity · MoA | 30 | Browse → |
| Methylxanthine · EPC | 30 | Browse → |
| Xanthines · CS | 30 | Browse → |
| Arteriolar Vasodilation · PE | 29 | Browse → |
| Arteriolar Vasodilator · EPC | 29 | Browse → |
| General Anesthesia · PE | 29 | Browse → |
| Nucleoside Reverse Transcriptase Inhibitors · MoA | 29 | Browse → |
| Platelet Aggregation Inhibitor · EPC | 29 | Browse → |
| Tricyclic Antidepressant · EPC | 29 | Browse → |
| Tetracyclines · CS | 28 | Browse → |
| Cytochrome P450 1A2 Inducers · MoA | 27 | Browse → |
| Dipeptidyl Peptidase 4 Inhibitor · EPC | 27 | Browse → |
| Dipeptidyl Peptidase 4 Inhibitors · MoA | 27 | Browse → |
| Decreased Cell Wall Integrity · PE | 26 | Browse → |
| Nucleic Acid Synthesis Inhibitors · MoA | 26 | Browse → |
| Serotonin and Norepinephrine Reuptake Inhibitor · EPC | 26 | Browse → |
| DNA Polymerase Inhibitors · MoA | 25 | Browse → |
| Dihydrofolate Reductase Inhibitors · MoA | 25 | Browse → |
| Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor · EPC | 25 | Browse → |
| Partial Opioid Agonists · MoA | 25 | Browse → |
| Cholinesterase Inhibitor · EPC | 24 | Browse → |
| Cholinesterase Inhibitors · MoA | 24 | Browse → |
| Neuromuscular Blockade · PE | 24 | Browse → |
| Alkylating Activity · MoA | 23 | Browse → |
| Alkylating Drug · EPC | 23 | Browse → |
| Blood Coagulation Factor · EPC | 23 | Browse → |
| Calcium · CS | 23 | Browse → |
| Cations · EPC | 23 | Browse → |
| Divalent · CS | 23 | Browse → |
| Increased Coagulation Factor Activity · PE | 23 | Browse → |
| Centrally-mediated Muscle Relaxation · PE | 22 | Browse → |
| Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor · EPC | 22 | Browse → |
| Muscle Relaxant · EPC | 22 | Browse → |
| Nucleoside Metabolic Inhibitor · EPC | 22 | Browse → |
| Serotonin 3 Receptor Antagonists · MoA | 22 | Browse → |
| Serotonin-3 Receptor Antagonist · EPC | 22 | Browse → |
| Topoisomerase Inhibitors · MoA | 22 | Browse → |
| Cytochrome P450 2C8 Inducers · MoA | 21 | Browse → |
| Decreased Blood Pressure · PE | 21 | Browse → |
| Folate Analog Metabolic Inhibitor · EPC | 21 | Browse → |
| Insulin Analog · EPC | 21 | Browse → |
| Insulin · CS | 21 | Browse → |
| Phosphodiesterase 5 Inhibitor · EPC | 21 | Browse → |
| Phosphodiesterase 5 Inhibitors · MoA | 21 | Browse → |
| Adrenergic alpha-Antagonists · MoA | 20 | Browse → |
| Calcineurin Inhibitor Immunosuppressant · EPC | 20 | Browse → |
| Calcineurin Inhibitors · MoA | 20 | Browse → |
| Fluoroquinolone Antibacterial · EPC | 20 | Browse → |
| Fluoroquinolones · CS | 20 | Browse → |
| Peroxisome Proliferator Receptor alpha Agonist · EPC | 20 | Browse → |
| alpha-Adrenergic Blocker · EPC | 20 | Browse → |
| Folic Acid Metabolism Inhibitors · MoA | 19 | Browse → |
| Histamine-1 Receptor Inhibitor · EPC | 19 | Browse → |
| Lincosamide Antibacterial · EPC | 19 | Browse → |
| Lincosamides · CS | 19 | Browse → |
| Opioid Antagonist · EPC | 19 | Browse → |
| Opioid Antagonists · MoA | 19 | Browse → |
| Organic Anion Transporting Polypeptide 1B1 Inhibitors · MoA | 19 | Browse → |
| Partial Opioid Agonist · EPC | 19 | Browse → |
| Radiographic Contrast Agent · EPC | 19 | Browse → |
| Tetracycline-class Drug · EPC | 19 | Browse → |
| X-Ray Contrast Activity · MoA | 19 | Browse → |
| Microtubule Inhibition · PE | 18 | Browse → |
| Sulfonamides · CS | 18 | Browse → |
| Antimalarial · EPC | 17 | Browse → |
| General Anesthetic · EPC | 17 | Browse → |
| Increased Norepinephrine Activity · PE | 17 | Browse → |
| Increased Sympathetic Activity · PE | 17 | Browse → |
| Interleukin-23 Antagonist · EPC | 17 | Browse → |
| Interleukin-23 Antagonists · MoA | 17 | Browse → |
| Radiopharmaceutical Activity · MoA | 17 | Browse → |
| Decreased Histamine Release · PE | 16 | Browse → |
| Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor · EPC | 16 | Browse → |
| Macrolide · EPC | 16 | Browse → |
| Mast Cell Stabilizer · EPC | 16 | Browse → |
| Quinolone Antimicrobial · EPC | 16 | Browse → |
| Quinolones · CS | 16 | Browse → |
| Radioactive Diagnostic Agent · EPC | 16 | Browse → |
| Sodium-Glucose Cotransporter 2 Inhibitor · EPC | 16 | Browse → |
| Sodium-Glucose Transporter 2 Inhibitors · MoA | 16 | Browse → |
| Antihistamine · EPC | 15 | Browse → |
| Bisphosphonate · EPC | 15 | Browse → |
| Carbonic Anhydrase Inhibitors · MoA | 15 | Browse → |
| Diphosphonates · CS | 15 | Browse → |
| GLP-1 Receptor Agonist · EPC | 15 | Browse → |
| Glucagon-like Peptide-1 (GLP-1) Agonists · MoA | 15 | Browse → |
| Histamine Receptor Antagonists · MoA | 15 | Browse → |
| Janus Kinase Inhibitor · EPC | 15 | Browse → |
| Janus Kinase Inhibitors · MoA | 15 | Browse → |
| Nitrate Vasodilator · EPC | 15 | Browse → |
| Nitrates · CS | 15 | Browse → |
| Nitroimidazole Antimicrobial · EPC | 15 | Browse → |
| Nitroimidazoles · CS | 15 | Browse → |
| Nucleosides · CS | 15 | Browse → |
| beta Lactamase Inhibitor · EPC | 15 | Browse → |
| beta Lactamase Inhibitors · MoA | 15 | Browse → |
| Acidifying Activity · MoA | 14 | Browse → |
| Androgen Receptor Agonists · MoA | 14 | Browse → |
| Androgen · EPC | 14 | Browse → |
| Androstanes · CS | 14 | Browse → |
| Anti-coagulant · EPC | 14 | Browse → |
| Antibodies · EPC | 14 | Browse → |
| Appetite Suppression · PE | 14 | Browse → |
| Central Nervous System Depression · PE | 14 | Browse → |
| Dopamine Uptake Inhibitors · MoA | 14 | Browse → |
| GABA A Agonists · MoA | 14 | Browse → |
| HIV Protease Inhibitors · MoA | 14 | Browse → |
| Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor · EPC | 14 | Browse → |
| Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor · EPC | 14 | Browse → |
| Interleukin-12 Antagonist · EPC | 14 | Browse → |
| Interleukin-12 Antagonists · MoA | 14 | Browse → |
| Iron Chelating Activity · MoA | 14 | Browse → |
| Iron Chelator · EPC | 14 | Browse → |
| Monoclonal · CS | 14 | Browse → |
| Prostaglandin Analog · EPC | 14 | Browse → |
| Prostaglandins · CS | 14 | Browse → |
| Protease Inhibitor · EPC | 14 | Browse → |
| UGT1A1 Inhibitors · MoA | 14 | Browse → |
| Aminoketone · EPC | 13 | Browse → |
| Barbiturate · EPC | 13 | Browse → |
| Barbiturates · CS | 13 | Browse → |
| Bile Acid Sequestrant · EPC | 13 | Browse → |
| Bile-acid Binding Activity · MoA | 13 | Browse → |
| Carbonic Anhydrase Inhibitor · EPC | 13 | Browse → |
| GABA A Receptor Positive Modulators · MoA | 13 | Browse → |
| Increased Dopamine Activity · PE | 13 | Browse → |
| Microtubule Inhibitor · EPC | 13 | Browse → |
| Peroxisome Proliferator-activated Receptor alpha Agonists · MoA | 13 | Browse → |
| Polyenes · CS | 13 | Browse → |
| Sympathomimetic Amine Anorectic · EPC | 13 | Browse → |
| Vascular Endothelial Growth Factor Inhibitor · EPC | 13 | Browse → |
| Vascular Endothelial Growth Factor Inhibitors · MoA | 13 | Browse → |
| gamma-Aminobutyric Acid-ergic Agonist · EPC | 13 | Browse → |
| Alkalinizing Activity · MoA | 12 | Browse → |
| Cytochrome P450 2D6 Inducers · MoA | 12 | Browse → |
| Ergocalciferols · CS | 12 | Browse → |
| Glucagon-Like Peptide 1 · CS | 12 | Browse → |
| Increased Diuresis at Loop of Henle · PE | 12 | Browse → |
| Inhibit Ovum Fertilization · PE | 12 | Browse → |
| Loop Diuretic · EPC | 12 | Browse → |
| Polyene Antifungal · EPC | 12 | Browse → |
| Sulfonylurea Compounds · CS | 12 | Browse → |
| Sulfonylurea · EPC | 12 | Browse → |
| Allylamine Antifungal · EPC | 11 | Browse → |
| Allylamine · CS | 11 | Browse → |
| Amino Acids · EPC | 11 | Browse → |
| Anthracycline Topoisomerase Inhibitor · EPC | 11 | Browse → |
| Anthracyclines · CS | 11 | Browse → |
| Aromatic Amino Acid · EPC | 11 | Browse → |
| Aromatic · CS | 11 | Browse → |
| Decreased Immunologic Activity · PE | 11 | Browse → |
| Leukocyte Growth Factor · EPC | 11 | Browse → |
| Neuromuscular Nondepolarizing Blockade · PE | 11 | Browse → |
| Nondepolarizing Neuromuscular Blocker · EPC | 11 | Browse → |
| Peroxisome Proliferator Receptor gamma Agonist · EPC | 11 | Browse → |
| Peroxisome Proliferator-activated Receptor gamma Agonists · MoA | 11 | Browse → |
| Selective Estrogen Receptor Modulators · MoA | 11 | Browse → |
| Thiazolidinedione · EPC | 11 | Browse → |
| Thiazolidinediones · CS | 11 | Browse → |
| Thyroxine · CS | 11 | Browse → |
| Topoisomerase Inhibitor · EPC | 11 | Browse → |
| UGT1A9 Inhibitors · MoA | 11 | Browse → |
| UGT2B7 Inhibitors · MoA | 11 | Browse → |
| gamma-Aminobutyric Acid A Receptor Positive Modulator · EPC | 11 | Browse → |
| l-Thyroxine · EPC | 11 | Browse → |
| mTOR Inhibitor Immunosuppressant · EPC | 11 | Browse → |
| mTOR Inhibitors · MoA | 11 | Browse → |
| Aldosterone Antagonist · EPC | 10 | Browse → |
| Aldosterone Antagonists · MoA | 10 | Browse → |
| Aminosalicylate · EPC | 10 | Browse → |
| Aminosalicylic Acids · CS | 10 | Browse → |
| Antiprotozoal · EPC | 10 | Browse → |
| Bcr-Abl Tyrosine Kinase Inhibitors · MoA | 10 | Browse → |
| Cholinergic Receptor Agonist · EPC | 10 | Browse → |
| Direct Thrombin Inhibitor · EPC | 10 | Browse → |
| Endothelin Receptor Antagonist · EPC | 10 | Browse → |
| Endothelin Receptor Antagonists · MoA | 10 | Browse → |
| Factor Xa Inhibitor · EPC | 10 | Browse → |
| Factor Xa Inhibitors · MoA | 10 | Browse → |
| Granulocyte Colony-Stimulating Factor · CS | 10 | Browse → |
| Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor · EPC | 10 | Browse → |
| Increased Myeloid Cell Production · PE | 10 | Browse → |
| Influenza A M2 Protein Inhibitor · EPC | 10 | Browse → |
| Iron · CS | 10 | Browse → |
| Kinase Inhibitors · MoA | 10 | Browse → |
| Leukotriene Receptor Antagonist · EPC | 10 | Browse → |
| Leukotriene Receptor Antagonists · MoA | 10 | Browse → |
| M2 Protein Inhibitors · MoA | 10 | Browse → |
| N-methyl-D-aspartate Receptor Antagonist · EPC | 10 | Browse → |
| NMDA Receptor Antagonists · MoA | 10 | Browse → |
| Non-Nucleoside Analog · EPC | 10 | Browse → |
| Non-Nucleoside Reverse Transcriptase Inhibitors · MoA | 10 | Browse → |
| Organic Anion Transporting Polypeptide 1B3 Inhibitors · MoA | 10 | Browse → |
| P2Y12 Platelet Inhibitor · EPC | 10 | Browse → |
| P2Y12 Receptor Antagonists · MoA | 10 | Browse → |
| Parenteral Iron Replacement · EPC | 10 | Browse → |
| Thrombin Inhibitors · MoA | 10 | Browse → |
| Tumor Necrosis Factor Blocker · EPC | 10 | Browse → |
| Tumor Necrosis Factor Receptor Blocking Activity · MoA | 10 | Browse → |
| Typical Antipsychotic · EPC | 10 | Browse → |
| Vasopressins · CS | 10 | Browse → |
| Vitamin D Analog · EPC | 10 | Browse → |
| Adrenergic alpha1-Agonists · MoA | 9 | — |
| Dopamine Agonists · MoA | 9 | — |
| Estrogen Agonist/Antagonist · EPC | 9 | — |
| Glycopeptide Antibacterial · EPC | 9 | — |
| Glycopeptides · CS | 9 | — |
| Lipopeptides · CS | 9 | — |
| Multidrug and Toxin Extrusion Transporter 1 Inhibitors · MoA | 9 | — |
| Neuraminidase Inhibitor · EPC | 9 | — |
| Neuraminidase Inhibitors · MoA | 9 | — |
| Nitrofuran Antibacterial · EPC | 9 | — |
| Nitrofurans · CS | 9 | — |
| Nonergot Dopamine Agonist · EPC | 9 | — |
| Nucleoside Analog Antiviral · EPC | 9 | — |
| alpha-1 Adrenergic Agonist · EPC | 9 | — |
| Antifibrinolytic Agent · EPC | 8 | — |
| Antirheumatic Agent · EPC | 8 | — |
| Cholinergic Agonists · MoA | 8 | — |
| Cholinergic Muscarinic Agonists · MoA | 8 | — |
| Cystine Disulfide Reduction · MoA | 8 | — |
| Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor · EPC | 8 | — |
| Decreased Fibrinolysis · PE | 8 | — |
| Dihydrofolate Reductase Inhibitor Antibacterial · EPC | 8 | — |
| Dopamine D2 Antagonists · MoA | 8 | — |
| Dopamine-2 Receptor Antagonist · EPC | 8 | — |
| Folate Analog · EPC | 8 | — |
| Folic Acid · CS | 8 | — |
| GABA B Agonists · MoA | 8 | — |
| Increased Megakaryocyte Maturation · PE | 8 | — |
| Increased Platelet Production · PE | 8 | — |
| Monoamine Oxidase Inhibitor · EPC | 8 | — |
| Monoamine Oxidase Inhibitors · MoA | 8 | — |
| Progestin-containing Intrauterine System · EPC | 8 | — |
| Prostacycline Vasodilator · EPC | 8 | — |
| Prostaglandins I · CS | 8 | — |
| Thrombopoietin Receptor Agonist · EPC | 8 | — |
| Thrombopoietin Receptor Agonists · MoA | 8 | — |
| Vasodilator · EPC | 8 | — |
| Vitamin D2 Analog · EPC | 8 | — |
| Antimetabolite Immunosuppressant · EPC | 7 | — |
| Aromatase Inhibitor · EPC | 7 | — |
| Aromatase Inhibitors · MoA | 7 | — |
| Carbapenems · CS | 7 | — |
| Cholecalciferol · CS | 7 | — |
| Cyclooxygenase Inhibitor · EPC | 7 | — |
| Cytochrome P450 3A5 Inhibitors · MoA | 7 | — |
| Decreased Protein Synthesis · PE | 7 | — |
| Increased Erythroid Cell Production · PE | 7 | — |
| Inhibition Gastric Acid Secretion · PE | 7 | — |
| Penem Antibacterial · EPC | 7 | — |
| Platinum-based Drug · EPC | 7 | — |
| Platinum-containing Compounds · EPC | 7 | — |
| Potassium Channel Antagonists · MoA | 7 | — |
| Progestin-containing Intrauterine Device · EPC | 7 | — |
| Prostaglandin E1 Analog · EPC | 7 | — |
| Prostaglandins E · EPC | 7 | — |
| Protein Synthesis Inhibitors · MoA | 7 | — |
| Somatostatin Analog · EPC | 7 | — |
| Somatostatin Receptor Agonists · MoA | 7 | — |
| Synthetic · CS | 7 | — |
| Thiazide-like Diuretic · EPC | 7 | — |
| UGT1A3 Inhibitors · MoA | 7 | — |
| UGT1A4 Inhibitors · MoA | 7 | — |
| UGT1A6 Inhibitors · MoA | 7 | — |
| UGT2B15 Inhibitors · MoA | 7 | — |
| Vitamin D3 Analog · EPC | 7 | — |
| Xanthine Oxidase Inhibitor · EPC | 7 | — |
| Xanthine Oxidase Inhibitors · MoA | 7 | — |
| 5-alpha Reductase Inhibitor · EPC | 6 | — |
| 5-alpha Reductase Inhibitors · MoA | 6 | — |
| Acetylcholine Release Inhibitor · EPC | 6 | — |
| Acetylcholine Release Inhibitors · MoA | 6 | — |
| Antidote · EPC | 6 | — |
| Bile Acid · EPC | 6 | — |
| Bile Acids and Salts · CS | 6 | — |
| CD20-directed Antibody Interactions · MoA | 6 | — |
| Cardiac Glycoside · EPC | 6 | — |
| Cardiac Glycosides · CS | 6 | — |
| Competitive Opioid Antagonists · MoA | 6 | — |
| Echinocandin Antifungal · EPC | 6 | — |
| Endoglycosidase · EPC | 6 | — |
| Epoxide Hydrolase Inhibitors · MoA | 6 | — |
| Ergolines · CS | 6 | — |
| Ergot Derivative · EPC | 6 | — |
| Erythropoiesis-stimulating Agent · EPC | 6 | — |
| Erythropoietin · CS | 6 | — |
| Factor VIII Activator · EPC | 6 | — |
| Glycoside Hydrolases · CS | 6 | — |
| HER2/Neu/cerbB2 Antagonists · MoA | 6 | — |
| HER2/neu Receptor Antagonist · EPC | 6 | — |
| Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor · EPC | 6 | — |
| Increased Coagulation Factor VIII Activity · PE | 6 | — |
| Increased Coagulation Factor VIII Concentration · PE | 6 | — |
| Interleukin 6 Receptor Antagonists · MoA | 6 | — |
| Interleukin-6 Receptor Antagonist · EPC | 6 | — |
| Magnetic Resonance Contrast Activity · MoA | 6 | — |
| Neurokinin 1 Antagonists · MoA | 6 | — |
| Organic Anion Transporter 3 Inhibitors · MoA | 6 | — |
| Poly(ADP-Ribose) Polymerase Inhibitor · EPC | 6 | — |
| Poly(ADP-Ribose) Polymerase Inhibitors · MoA | 6 | — |
| RNA Replicase Inhibitors · MoA | 6 | — |
| Substance P/Neurokinin-1 Receptor Antagonist · EPC | 6 | — |
| Sulfonamide Antibacterial · EPC | 6 | — |
| Tetracycline-class Antimicrobial · EPC | 6 | — |
| Tyrosine Kinase Inhibitors · MoA | 6 | — |
| Vascular Endothelial Growth Factor-directed Antibody Interactions · MoA | 6 | — |
| Vasoconstriction · PE | 6 | — |
| Vasopressin Analog · EPC | 6 | — |
| Adenosine Receptor Agonists · MoA | 5 | — |
| Amino Acid · EPC | 5 | — |
| Amino Acids · CS | 5 | — |
| Ammonium Ion Binding Activity · MoA | 5 | — |
| Androgen Receptor Antagonists · MoA | 5 | — |
| Androgen Receptor Inhibitor · EPC | 5 | — |
| Antimetabolite · EPC | 5 | — |
| Antimycobacterial · EPC | 5 | — |
| CD20-directed Cytolytic Antibody · EPC | 5 | — |
| Calcium-sensing Receptor Agonist · EPC | 5 | — |
| Catechol O-Methyltransferase Inhibitors · MoA | 5 | — |
| Catechol-O-Methyltransferase Inhibitor · EPC | 5 | — |
| Conjugated (USP) · CS | 5 | — |
| Cytochrome P450 17A1 Inhibitor · EPC | 5 | — |
| Cytochrome P450 17A1 Inhibitors · MoA | 5 | — |
| Cytochrome P450 1A1 Inhibitors · MoA | 5 | — |
| Cytochrome P450 2D6 Inhibitor · EPC | 5 | — |
| Cytochrome P450 3A Inhibitor · EPC | 5 | — |
| Cytoprotective Agent · EPC | 5 | — |
| Decreased DNA Replication · PE | 5 | — |
| Decreased Mitosis · PE | 5 | — |
| Decreased Prothrombin Activity · PE | 5 | — |
| Decreased RNA Replication · PE | 5 | — |
| Decreased Renal K+ Excretion · PE | 5 | — |
| Ester Local Anesthetic · EPC | 5 | — |
| Esters · CS | 5 | — |
| Estrogens · EPC | 5 | — |
| Heparin · CS | 5 | — |
| Increased Calcium-sensing Receptor Sensitivity · MoA | 5 | — |
| Insulin [Chemical/Ingredient] · EPC | 5 | — |
| Insulin · EPC | 5 | — |
| Neuromuscular Blocker · EPC | 5 | — |
| Nitrogen Binding Agent · EPC | 5 | — |
| Opioid Agonist/Antagonist · EPC | 5 | — |
| Oxazolidinone Antibacterial · EPC | 5 | — |
| Oxazolidinones · CS | 5 | — |
| Pediculicide · EPC | 5 | — |
| Phenylalanine Hydroxylase Activator · EPC | 5 | — |
| Phenylalanine Hydroxylase Activators · MoA | 5 | — |
| Phosphodiesterase 3 Inhibitors · MoA | 5 | — |
| Potassium-sparing Diuretic · EPC | 5 | — |
| Programmed Death Receptor-1 Blocking Antibody · EPC | 5 | — |
| Programmed Death Receptor-1-directed Antibody Interactions · MoA | 5 | — |
| Prostaglandin Receptor Agonists · MoA | 5 | — |
| Purine Antimetabolite · EPC | 5 | — |
| Pyridines · CS | 5 | — |
| Pyridone · EPC | 5 | — |
| Pyridones · CS | 5 | — |
| Skin Barrier Activity · PE | 5 | — |
| Sphingosine 1-Phosphate Receptor Modulators · MoA | 5 | — |
| Sphingosine 1-phosphate Receptor Modulator · EPC | 5 | — |
| Tubulin Inhibiting Agent · EPC | 5 | — |
| Unfractionated Heparin · EPC | 5 | — |
| Vesicular Monoamine Transporter 2 Inhibitor · EPC | 5 | — |
| Vesicular Monoamine Transporter 2 Inhibitors · MoA | 5 | — |
| Vitamin D · CS | 5 | — |
| AMPA Receptor Antagonists · MoA | 4 | — |
| Adrenergic beta1-Antagonists · MoA | 4 | — |
| Adrenergic beta2-Antagonists · MoA | 4 | — |
| Adrenocorticotropic Hormone · CS | 4 | — |
| Adrenocorticotropic Hormone · EPC | 4 | — |
| Alkaloid · EPC | 4 | — |
| Alkaloids · CS | 4 | — |
| Angiotensin 2 Type 1 Receptor Antagonists · MoA | 4 | — |
| Antidote for Acetaminophen Overdose · EPC | 4 | — |
| Antiemetic · EPC | 4 | — |
| Antisense Oligonucleotide · EPC | 4 | — |
| Antisense · CS | 4 | — |
| Benzylamine Antifungal · EPC | 4 | — |
| Benzylamines · CS | 4 | — |
| Calcitonin Gene-related Peptide Receptor Antagonist · EPC | 4 | — |
| Calcitonin Gene-related Peptide Receptor Antagonists · MoA | 4 | — |
| Cannabinoid · EPC | 4 | — |
| Cannabinoids · CS | 4 | — |
| Cardiac Rhythm Alteration · PE | 4 | — |
| Chloride Channel Activation Potentiators · MoA | 4 | — |
| Copper Absorption Inhibitor · EPC | 4 | — |
| Cystic Fibrosis Transmembrane Conductance Regulator Potentiator · EPC | 4 | — |
| Cystine Depleting Agent · EPC | 4 | — |
| Cytochrome P450 2B6 Inhibitors · MoA | 4 | — |
| Decreased Copper Ion Absorption · PE | 4 | — |
| Decreased Diuresis · PE | 4 | — |
| Decreased Tracheobronchial Stretch Receptor Activity · PE | 4 | — |
| Depolarizing Neuromuscular Blocker · EPC | 4 | — |
| Emesis Suppression · PE | 4 | — |
| Gadolinium-based Contrast Agent · EPC | 4 | — |
| Genitourinary Arterial Vasodilation · PE | 4 | — |
| Glinide · EPC | 4 | — |
| Gonadotropin Releasing Hormone Receptor Agonist · EPC | 4 | — |
| Gonadotropin Releasing Hormone Receptor Agonists · MoA | 4 | — |
| Heparin · EPC | 4 | — |
| Hepatitis C Virus NS5A Inhibitor · EPC | 4 | — |
| Human Growth Hormone · CS | 4 | — |
| Ileal Bile Acid Transporter Inhibitor · EPC | 4 | — |
| Ileal Bile Acid Transporter Inhibitors · MoA | 4 | — |
| Increased Glutathione Concentration · PE | 4 | — |
| Low Molecular Weight Heparin · EPC | 4 | — |
| Low-Molecular-Weight · CS | 4 | — |
| Monoamine Oxidase Type B Inhibitor · EPC | 4 | — |
| Monoamine Oxidase-B Inhibitors · MoA | 4 | — |
| Mucolytic · EPC | 4 | — |
| N-substituted Glycines · CS | 4 | — |
| Neprilysin Inhibitor · EPC | 4 | — |
| Neprilysin Inhibitors · MoA | 4 | — |
| Neuromuscular Depolarizing Blockade · PE | 4 | — |
| Non-narcotic Antitussive · EPC | 4 | — |
| Noncompetitive AMPA Glutamate Receptor Antagonist · EPC | 4 | — |
| Norepinephrine Releasing Agent · EPC | 4 | — |
| Norepinephrine Reuptake Inhibitor · EPC | 4 | — |
| Organic Anion Transporter 1 Inhibitors · MoA | 4 | — |
| Organic Anion Transporting Polypeptide 2B1 Inhibitors · MoA | 4 | — |
| P-Glycoprotein Inducers · MoA | 4 | — |
| Parathyroid Hormone Analog · EPC | 4 | — |
| Parathyroid Hormone · CS | 4 | — |
| Partial Cholinergic Nicotinic Agonist · EPC | 4 | — |
| Partial Cholinergic Nicotinic Agonists · MoA | 4 | — |
| Phosphodiesterase 3 Inhibitor · EPC | 4 | — |
| Phosphodiesterase 4 Inhibitor · EPC | 4 | — |
| Phosphodiesterase 4 Inhibitors · MoA | 4 | — |
| Progesterone · CS | 4 | — |
| Progesterone · EPC | 4 | — |
| Prostaglandin E1 Agonist · EPC | 4 | — |
| Proteasome Inhibitor · EPC | 4 | — |
| Proteasome Inhibitors · MoA | 4 | — |
| Provitamin D2 Compound · EPC | 4 | — |
| Receptor Tyrosine Kinase Inhibitors · MoA | 4 | — |
| Recombinant Human Growth Hormone · EPC | 4 | — |
| Reducing and Complexing Thiol · EPC | 4 | — |
| Reduction Activity · MoA | 4 | — |
| Reversed Anticoagulation Activity · PE | 4 | — |
| Rifamycins · CS | 4 | — |
| Serotonin 4 Receptor Agonists · MoA | 4 | — |
| Serotonin-4 Receptor Agonist · EPC | 4 | — |
| Sulfonamide Antimicrobial · EPC | 4 | — |
| Thalidomide Analog · EPC | 4 | — |
| UDP Glucuronosyltransferases Inducers · MoA | 4 | — |
| Urea · CS | 4 | — |
| Venous Vasodilation · PE | 4 | — |
| gamma-Cyclodextrins · CS | 4 | — |
| 4-Hydroxyphenyl-Pyruvate Dioxygenase Inhibitor · EPC | 3 | — |
| Adenosine Receptor Agonist · EPC | 3 | — |
| Adrenergic beta3-Agonists · MoA | 3 | — |
| Anti-IgE · EPC | 3 | — |
| Antihypoglycemic Agent · EPC | 3 | — |
| Antiparasitic · EPC | 3 | — |
| Calcitonin · CS | 3 | — |
| Calcitonin · EPC | 3 | — |
| Calcium Chelating Activity · MoA | 3 | — |
| Carnitine Analog · EPC | 3 | — |
| Carnitine · CS | 3 | — |
| Chelating Activity · MoA | 3 | — |
| Chloride Channel Activator · EPC | 3 | — |
| Chloride Channel Activators · MoA | 3 | — |
| Cytochrome P450 2E1 Inducers · MoA | 3 | — |
| Cytomegalovirus DNA Terminase Complex Inhibitor · EPC | 3 | — |
| DNA Terminase Complex Inhibitors · MoA | 3 | — |
| Decreased Cholesterol Absorption · PE | 3 | — |
| Decreased Coagulation Factor Activity · PE | 3 | — |
| Decreased GnRH Secretion · PE | 3 | — |
| Decreased IgE Activity · PE | 3 | — |
| Diagnostic Dye · EPC | 3 | — |
| Dietary Cholesterol Absorption Inhibitor · EPC | 3 | — |
| Dihydroorotate Dehydrogenase Inhibitors · MoA | 3 | — |
| Dyes · MoA | 3 | — |
| Ergotamine Derivative · EPC | 3 | — |
| Ergotamines · CS | 3 | — |
| Estrogen Receptor Antagonist · EPC | 3 | — |
| Estrogen Receptor Antagonists · MoA | 3 | — |
| Fatty Acids · EPC | 3 | — |
| Gonadotropin Releasing Hormone Receptor Antagonist · EPC | 3 | — |
| Gonadotropin Releasing Hormone Receptor Antagonists · MoA | 3 | — |
| Guanylate Cyclase Stimulators · MoA | 3 | — |
| HIV Integrase Inhibitors · MoA | 3 | — |
| Hematopoietic Stem Cell Mobilizer · EPC | 3 | — |
| Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor · EPC | 3 | — |
| Hydroxyphenylpyruvate Dioxygenase Inhibitors · MoA | 3 | — |
| Hyperpolarization-activated Cyclic Nucleotide-gated Channel Antagonists · MoA | 3 | — |
| Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker · EPC | 3 | — |
| IgE-directed Antibody Interactions · MoA | 3 | — |
| Increased Cytokine Activity · PE | 3 | — |
| Increased Glycogenolysis · PE | 3 | — |
| Increased Hematopoietic Stem Cell Mobilization · PE | 3 | — |
| Increased Prothrombin Activity · PE | 3 | — |
| Increased Uterine Smooth Muscle Contraction or Tone · PE | 3 | — |
| Interferon beta · EPC | 3 | — |
| Interferon-beta · CS | 3 | — |
| Kallikrein Inhibitors · MoA | 3 | — |
| Lipopeptide Antibacterial · EPC | 3 | — |
| Melatonin Receptor Agonist · EPC | 3 | — |
| Melatonin Receptor Agonists · MoA | 3 | — |
| Mitogen-Activated Protein Kinase Kinase 1 Inhibitors · MoA | 3 | — |
| Mitogen-Activated Protein Kinase Kinase 2 Inhibitors · MoA | 3 | — |
| Multidrug and Toxin Extrusion Transporter 2 K Inhibitors · MoA | 3 | — |
| Nicotinic Acid · EPC | 3 | — |
| Nicotinic Acids · CS | 3 | — |
| Oligonucleotides · EPC | 3 | — |
| Omega-3 Fatty Acid · EPC | 3 | — |
| Omega-3 · CS | 3 | — |
| Orexin Receptor Antagonist · EPC | 3 | — |
| Orexin Receptor Antagonists · MoA | 3 | — |
| Organic Cation Transporter 1 Inhibitors · MoA | 3 | — |
| Oxidation-Reduction Activity · MoA | 3 | — |
| Oxidation-Reduction Agent · EPC | 3 | — |
| Oxytocic · EPC | 3 | — |
| Oxytocin · CS | 3 | — |
| PPAR alpha · CS | 3 | — |
| Plasma Kallikrein Inhibitor · EPC | 3 | — |
| Potassium Channel Blocker · EPC | 3 | — |
| Prostacyclin Receptor Agonist · EPC | 3 | — |
| Prostacyclin Receptor Agonists · MoA | 3 | — |
| Purines · CS | 3 | — |
| Pyrimidine Synthesis Inhibitor · EPC | 3 | — |
| Rearranged during Transfection (RET) Inhibitors · MoA | 3 | — |
| Rifamycin Antibacterial · EPC | 3 | — |
| Soluble Guanylate Cyclase Stimulator · EPC | 3 | — |
| Sulfone · EPC | 3 | — |
| Sulfones · CS | 3 | — |
| Tetracycline-class Antibacterial · EPC | 3 | — |
| Triiodothyronine · CS | 3 | — |
| UDP Glucuronosyltransferases Inhibitors · MoA | 3 | — |
| Vasopressin V2 Receptor Antagonist · EPC | 3 | — |
| Vasopressin V2 Receptor Antagonists · MoA | 3 | — |
| Vitamin K · CS | 3 | — |
| Vitamin K · EPC | 3 | — |
| Warfarin Reversal Agent · EPC | 3 | — |
| beta3-Adrenergic Agonist · EPC | 3 | — |
| l-Triiodothyronine · EPC | 3 | — |
| 5-Lipoxygenase Inhibitor · EPC | 2 | — |
| 5-Lipoxygenase Inhibitors · MoA | 2 | — |
| Allergens · CS | 2 | — |
| Aluminum Complex · EPC | 2 | — |
| Amyloid Beta-directed Antibody Interactions · MoA | 2 | — |
| Amyloid Beta-directed Antibody · EPC | 2 | — |
| Anthelmintic · EPC | 2 | — |
| Anti-anginal · EPC | 2 | — |
| Antidiarrheal · EPC | 2 | — |
| Benzodiazepine Antagonist · EPC | 2 | — |
| Bismuth · CS | 2 | — |
| Bismuth · EPC | 2 | — |
| Bradykinin B2 Receptor Antagonist · EPC | 2 | — |
| Bradykinin B2 Receptor Antagonists · MoA | 2 | — |
| CCR5 Co-receptor Antagonist · EPC | 2 | — |
| CTLA-4-directed Antibody Interactions · MoA | 2 | — |
| CTLA-4-directed Blocking Antibody · EPC | 2 | — |
| Cell-mediated Immunity · PE | 2 | — |
| Central Nervous System Depressant · EPC | 2 | — |
| Chemokine Co-receptor 5 Antagonists · MoA | 2 | — |
| Cholinergic Muscarinic Agonist · EPC | 2 | — |
| Colony Stimulating Factor Receptor Type 1 (CSF-1R) Inhibitors · MoA | 2 | — |
| Complement Inhibitor · EPC | 2 | — |
| Complement Inhibitors · MoA | 2 | — |
| Cytochrome P450 1A Inducers · MoA | 2 | — |
| Decreased Central Nervous System Organized Electrical Activity · PE | 2 | — |
| Decreased GI Motility · PE | 2 | — |
| Decreased GI Smooth Muscle Tone · PE | 2 | — |
| Decreased Glycolysis · PE | 2 | — |
| Decreased Leukotriene Production · PE | 2 | — |
| Decreased Parasympathetic Acetylcholine Activity · PE | 2 | — |
| Decreased RNA Integrity · PE | 2 | — |
| Decreased Striated Muscle Contraction · PE | 2 | — |
| Decreased Striated Muscle Tone · PE | 2 | — |
| Digestive/GI System Activity Alteration · PE | 2 | — |
| Dihydrofolate Reductase Inhibitor Antimalarial · EPC | 2 | — |
| Epidermal Growth Factor Receptor Antagonist · EPC | 2 | — |
| Fibroblast Growth Factor Receptor Inhibitors · MoA | 2 | — |
| G-Protein-linked Receptor Interactions · MoA | 2 | — |
| GI Motility Alteration · PE | 2 | — |
| Gastrointestinal Motility Inhibitor · EPC | 2 | — |
| Glucose-dependent Insulinotropic Polypeptide Receptor Agonist · EPC | 2 | — |
| Gonadotropin · EPC | 2 | — |
| Gonadotropins · CS | 2 | — |
| HER1 Antagonists · MoA | 2 | — |
| Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors · MoA | 2 | — |
| Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor · EPC | 2 | — |
| Increased Blood Pressure · PE | 2 | — |
| Increased Cytokine Production · PE | 2 | — |
| Increased Gluconeogenesis · PE | 2 | — |
| Increased Histamine Release · PE | 2 | — |
| Increased RNA Degradation · PE | 2 | — |
| Increased T Lymphocyte Activation · PE | 2 | — |
| Inhalation Diagnostic Agent · EPC | 2 | — |
| Interferon Inducers · MoA | 2 | — |
| Interleukin-13 Antagonist · EPC | 2 | — |
| Interleukin-13 Antagonists · MoA | 2 | — |
| Interleukin-17A Antagonist · EPC | 2 | — |
| Interleukin-17A Antagonists · MoA | 2 | — |
| Intestinal Lipase Inhibitor · EPC | 2 | — |
| Isocitrate Dehydrogenase 2 Inhibitor · EPC | 2 | — |
| Isocitrate Dehydrogenase 2 Inhibitors · MoA | 2 | — |
| Lipase Inhibitors · MoA | 2 | — |
| Lipid-based Polyene Antifungal · EPC | 2 | — |
| Lipoglycopeptide Antibacterial · EPC | 2 | — |
| Lipoglycopeptides · CS | 2 | — |
| Monobactam Antibacterial · EPC | 2 | — |
| Monobactams · CS | 2 | — |
| Neonatal Fc Receptor Blocker · EPC | 2 | — |
| Neonatal Fc Receptor Blockers · MoA | 2 | — |
| Nucleoside Analog Antifungal · EPC | 2 | — |
| Organometallic Compounds · CS | 2 | — |
| Osmotic Diuretic · EPC | 2 | — |
| P-Glycoprotein Interactions · MoA | 2 | — |
| PCSK9 Inhibitor · EPC | 2 | — |
| PCSK9 Inhibitors · MoA | 2 | — |
| Pharmacologic Cardiac Stress Test Agent · EPC | 2 | — |
| Polymerase Acidic Endonuclease Inhibitor · EPC | 2 | — |
| Polymerase Acidic Endonuclease Inhibitors · MoA | 2 | — |
| RANK Ligand Blocking Activity · MoA | 2 | — |
| RANK Ligand Inhibitor · EPC | 2 | — |
| RNA Synthetase Inhibitor Antibacterial · EPC | 2 | — |
| RNA Synthetase Inhibitors · MoA | 2 | — |
| Renin Inhibitor · EPC | 2 | — |
| Renin Inhibitors · MoA | 2 | — |
| Skeletal Muscle Relaxant · EPC | 2 | — |
| Sodium Channel Antagonists · MoA | 2 | — |
| Sympathomimetic-like Agent · EPC | 2 | — |
| Thyroid Hormone Synthesis Inhibitor · EPC | 2 | — |
| Thyroid Hormone Synthesis Inhibitors · MoA | 2 | — |
| Tropomyosin Receptor Kinases Inhibitors · MoA | 2 | — |
| Vasoconstrictor · EPC | 2 | — |
| Vitamin B 12 · CS | 2 | — |
| Vitamin B12 · EPC | 2 | — |
| Vitamin K Antagonist · EPC | 2 | — |
| Vitamin K Inhibitors · MoA | 2 | — |
| alpha Glucosidase Inhibitors · MoA | 2 | — |
| alpha-Glucosidase Inhibitor · EPC | 2 | — |
| 11-beta Hydroxysteroid Dehydrogenase Type 1 Inhibitors · MoA | 1 | — |
| APOC-III-directed RNA Interaction · EPC | 1 | — |
| Acetyl Aldehyde Dehydrogenase Inhibitors · MoA | 1 | — |
| Actinomycin · EPC | 1 | — |
| Adrenal Steroid Synthesis Inhibitor · EPC | 1 | — |
| Adrenal Steroid Synthesis Inhibitors · MoA | 1 | — |
| Aldehyde Dehydrogenase Inhibitor · EPC | 1 | — |
| Alkaline Phosphatase · CS | 1 | — |
| Amphetamine Anorectic · EPC | 1 | — |
| Amphetamines · CS | 1 | — |
| Amylin Agonists · MoA | 1 | — |
| Amylin Analog · EPC | 1 | — |
| Analogs/Derivatives [Chemical/Ingredient] · EPC | 1 | — |
| Anthrax Protective Antigen-directed Antibody Interactions · MoA | 1 | — |
| Anthrax Protective Antigen-directed Antibody · EPC | 1 | — |
| Antibodies · CS | 1 | — |
| Antithrombin-directed RNA Interaction · EPC | 1 | — |
| Ascorbic Acid · CS | 1 | — |
| Autonomic Ganglionic Blocker · EPC | 1 | — |
| B Lymphocyte Stimulator-directed Antibody Interactions · MoA | 1 | — |
| B Lymphocyte Stimulator-specific Inhibitor · EPC | 1 | — |
| BCL-2 Inhibitor · EPC | 1 | — |
| Benzothiazole · EPC | 1 | — |
| Benzothiazoles · CS | 1 | — |
| Bile Salt Export Pump Inhibitors · MoA | 1 | — |
| Bispecific CD20-directed CD3 T Cell Engager · EPC | 1 | — |
| Blood Viscosity Reducer · EPC | 1 | — |
| Boron Compounds · CS | 1 | — |
| Bruton's Tyrosine Kinase Inhibitors · MoA | 1 | — |
| CD3 Receptor Agonists · MoA | 1 | — |
| CD3-directed Antibody Interactions · MoA | 1 | — |
| CD38-directed Antibody Interactions · MoA | 1 | — |
| CD38-directed Cytolytic Antibody · EPC | 1 | — |
| Carbamoyl Phosphate Synthetase 1 Activator · EPC | 1 | — |
| Carbamoyl Phosphate Synthetase 1 Activators · MoA | 1 | — |
| Cardiac Myosin Inhibitor · EPC | 1 | — |
| Cardiac Myosin Inhibitors · MoA | 1 | — |
| Catecholamine Synthesis Inhibitor · EPC | 1 | — |
| Catecholamine Synthesis Inhibitors · MoA | 1 | — |
| Cholecystokinin Analog · EPC | 1 | — |
| Cholecystokinin · CS | 1 | — |
| Claudin 18.2-directed Antibody Interactions · MoA | 1 | — |
| Claudin 18.2-directed Cytolytic Antibody · EPC | 1 | — |
| Colony Stimulating Factor-1 Receptor Blocker · EPC | 1 | — |
| Colony-Stimulating Factors · CS | 1 | — |
| Copper Chelating Activity · MoA | 1 | — |
| Copper Chelator · EPC | 1 | — |
| Copper · CS | 1 | — |
| Copper-containing Intrauterine Device · EPC | 1 | — |
| Cortisol Synthesis Inhibitor · EPC | 1 | — |
| Cyclin-dependent Kinase 4 Inhibitors · MoA | 1 | — |
| Cyclin-dependent Kinase 6 Inhibitors · MoA | 1 | — |
| Cytochrome P450 11B1 Inhibitors · MoA | 1 | — |
| Cytochrome P450 Inhibitors · MoA | 1 | — |
| Decreased Autonomic Ganglionic Activity · PE | 1 | — |
| Decreased B Lymphocyte Activation · PE | 1 | — |
| Decreased Cytokine Activity · PE | 1 | — |
| Decreased Embryonic Implantation · PE | 1 | — |
| Decreased Gastric Motility · PE | 1 | — |
| Decreased Immunologically Active Molecule Activity · PE | 1 | — |
| Decreased Platelet Production · PE | 1 | — |
| Decreased Sperm Motility · PE | 1 | — |
| Deoxyuridine · CS | 1 | — |
| Diarylquinoline Antimycobacterial · EPC | 1 | — |
| Diarylquinolines · CS | 1 | — |
| Dietary Proteins · CS | 1 | — |
| Dipeptidase Inhibitors · MoA | 1 | — |
| Dopamine and Norepinephrine Reuptake Inhibitor · EPC | 1 | — |
| Enzyme Stabilizer · EPC | 1 | — |
| Enzyme Stabilizers · MoA | 1 | — |
| Erythroid Maturation Agent · EPC | 1 | — |
| FMS-like Receptor Tyrosine Kinase 3 (FLT3) Inhibitors · MoA | 1 | — |
| Farnesyltransferase Inhibitor · EPC | 1 | — |
| Farnesyltransferase Inhibitors · MoA | 1 | — |
| Fibric Acids · CS | 1 | — |
| Fusion Protein Inhibitors · MoA | 1 | — |
| Gamma Secretase Inhibitor · EPC | 1 | — |
| Gamma Secretase Inhibitors · MoA | 1 | — |
| Glucagon Receptor Agonists · MoA | 1 | — |
| Glucosylceramide Synthase Inhibitor · EPC | 1 | — |
| Glucosylceramide Synthase Inhibitors · MoA | 1 | — |
| Granulocyte-Macrophage Colony-Stimulating Factor · CS | 1 | — |
| Growth Hormone Secretagogue Receptor Agonist · EPC | 1 | — |
| Growth Hormone Secretagogue Receptor Agonists · MoA | 1 | — |
| Guanylate Cyclase Activators · MoA | 1 | — |
| Guanylate Cyclase-C Agonist · EPC | 1 | — |
| Hedgehog Pathway Inhibitor · EPC | 1 | — |
| Hematologic Activity Alteration · PE | 1 | — |
| Hemoglobin S Polymerization Inhibitor · EPC | 1 | — |
| Hemoglobin S Polymerization Inhibitors · MoA | 1 | — |
| Heparin Binding Activity · MoA | 1 | — |
| Heparin Reversal Agent · EPC | 1 | — |
| Histamine H3 Receptor Antagonists · MoA | 1 | — |
| Histamine H3 Receptor Inverse Agonists · MoA | 1 | — |
| Histamine-3 Receptor Antagonist/Inverse Agonist · EPC | 1 | — |
| Humanized · CS | 1 | — |
| Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme · EPC | 1 | — |
| Hyperpolarized Contrast Agent · EPC | 1 | — |
| Imidazolines · CS | 1 | — |
| Increased Cellular Death · PE | 1 | — |
| Increased Gastric Muscle Tone · PE | 1 | — |
| Increased Prostaglandin Activity · PE | 1 | — |
| Increased Protein Breakdown · PE | 1 | — |
| Increased Protein Synthesis · PE | 1 | — |
| Interferon alpha · EPC | 1 | — |
| Interferon gamma Antagonists · MoA | 1 | — |
| Interferon gamma Blocker · EPC | 1 | — |
| Interferon-alpha · CS | 1 | — |
| Interleukin 2 Receptor Antagonists · MoA | 1 | — |
| Interleukin 2 Receptor-directed Antibody Interactions · MoA | 1 | — |
| Interleukin 4 Receptor alpha Antagonists · MoA | 1 | — |
| Interleukin 5 Receptor alpha-directed Antibody Interactions · MoA | 1 | — |
| Interleukin-2 Receptor Blocking Antibody · EPC | 1 | — |
| Interleukin-36 Receptor Antagonist · EPC | 1 | — |
| Interleukin-36 Receptor Antagonists · MoA | 1 | — |
| Interleukin-4 Receptor alpha Antagonist · EPC | 1 | — |
| Interleukin-5 Antagonist · EPC | 1 | — |
| Interleukin-5 Antagonists · MoA | 1 | — |
| Interleukin-5 Receptor alpha-directed Cytolytic Antibody · EPC | 1 | — |
| Interleukin-6 Antagonist · EPC | 1 | — |
| Interleukin-6 Antagonists · MoA | 1 | — |
| Isocitrate Dehydrogenase 1 Inhibitor · EPC | 1 | — |
| Isocitrate Dehydrogenase 1 Inhibitors · MoA | 1 | — |
| Janus Kinase 3 Inhibitors · MoA | 1 | — |
| Lipid Emulsion · EPC | 1 | — |
| Lipids · CS | 1 | — |
| Local Anesthetic · EPC | 1 | — |
| Lymphocyte Function-Associated Antigen-1 Antagonist · EPC | 1 | — |
| Lymphocyte Function-Associated Antigen-1 Antagonists · MoA | 1 | — |
| Lysosomal beta Glucuronidase · EPC | 1 | — |
| Macrolide Antibacterial · EPC | 1 | — |
| Menin Inhibitor · EPC | 1 | — |
| Menin Inhibitors · MoA | 1 | — |
| Mesenchymal Epithelial Transition Inhibitors · MoA | 1 | — |
| Metal Chelating Activity · MoA | 1 | — |
| Metal Chelator · EPC | 1 | — |
| Microsomal Triglyceride Transfer Protein Inhibitor · EPC | 1 | — |
| Microsomal Triglyceride Transfer Protein Inhibitors · MoA | 1 | — |
| Mineralocorticoid Receptor Antagonists · MoA | 1 | — |
| Monoclonal · EPC | 1 | — |
| N-Calcium Channel Receptor Antagonists · MoA | 1 | — |
| N-type Calcium Channel Antagonist · EPC | 1 | — |
| Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator · EPC | 1 | — |
| Neurokinin 3 Receptor Antagonist · EPC | 1 | — |
| Neurokinin 3 Receptor Antagonists · MoA | 1 | — |
| Non-Standardized Food Allergenic Extract · EPC | 1 | — |
| Non-Standardized Plant Allergenic Extract · EPC | 1 | — |
| Nonsteroidal Mineralocorticoid-Receptor Antagonist · EPC | 1 | — |
| Nuclear Export Inhibitor · EPC | 1 | — |
| Nuclear Export Inhibitors · MoA | 1 | — |
| Oligonucleotide Telomerase Inhibitor · EPC | 1 | — |
| Oligonucleotide Telomerase Inhibitors · MoA | 1 | — |
| Opioid mu-Receptor Agonists · MoA | 1 | — |
| Oxaborole Antifungal · EPC | 1 | — |
| PPAR gamma · CS | 1 | — |
| Paramagnetic Contrast Agent · EPC | 1 | — |
| Partial Opioid Agonist/Antagonist · EPC | 1 | — |
| Peroxisome Proliferator-activated Receptor Activity · MoA | 1 | — |
| Phenylalanine Ammonia-Lyase · CS | 1 | — |
| Phenylalanine Metabolizing Enzyme · EPC | 1 | — |
| Phosphoinositide 3-Kinase alpha Inhibitors · MoA | 1 | — |
| Photoabsorption · MoA | 1 | — |
| Photoenhancer · EPC | 1 | — |
| Photosensitizing Activity · PE | 1 | — |
| Plant Proteins · CS | 1 | — |
| Platelet-reducing Agent · EPC | 1 | — |
| Polyene Antimicrobial · EPC | 1 | — |
| Positron Emitting Activity · MoA | 1 | — |
| Potassium Binder · EPC | 1 | — |
| Potassium Ion Binding Activity · MoA | 1 | — |
| Progestational Hormone Receptor Antagonists · MoA | 1 | — |
| Progesterone Agonist/Antagonist · EPC | 1 | — |
| Progestin Antagonist · EPC | 1 | — |
| Programmed Death Ligand-1 Antagonists · MoA | 1 | — |
| Programmed Death Ligand-1 Blocker · EPC | 1 | — |
| Programmed Death Ligand-1-directed Antibody Interactions · MoA | 1 | — |
| Proto-Oncogene Tyrosine-Protein Kinase ROS1 Inhibitors · MoA | 1 | — |
| Pyrethrins · CS | 1 | — |
| Pyrethroid · EPC | 1 | — |
| Pyrophosphate Analog DNA Polymerase Inhibitor · EPC | 1 | — |
| Pyrophosphate Analog · EPC | 1 | — |
| Pyruvate Kinase Activator · EPC | 1 | — |
| Pyruvate Kinase Activators · MoA | 1 | — |
| Quaternary Ammonium Compounds · CS | 1 | — |
| RNA · EPC | 1 | — |
| Recombinant Fusion Proteins · CS | 1 | — |
| Renal Dehydropeptidase Inhibitor · EPC | 1 | — |
| Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody · EPC | 1 | — |
| Rifamycin Antimycobacterial · EPC | 1 | — |
| SLAMF7-directed Antibody Interactions · MoA | 1 | — |
| SLAMF7-directed Immunostimulatory Antibody · EPC | 1 | — |
| Sclerosing Activity · MoA | 1 | — |
| Sclerosing Agent · EPC | 1 | — |
| Seed Storage Proteins · CS | 1 | — |
| Selective Progesterone Receptor Modulators · MoA | 1 | — |
| Selective T Cell Costimulation Modulator · EPC | 1 | — |
| Small Interfering RNA · EPC | 1 | — |
| Small Interfering · CS | 1 | — |
| Smoothened Receptor Antagonists · MoA | 1 | — |
| Sodium Channel Blocker · EPC | 1 | — |
| Standardized Chemical Allergen · EPC | 1 | — |
| Survival Motor Neuron-2-directed RNA Interaction · EPC | 1 | — |
| Thymic Stromal Lymphopoietin Blocker · EPC | 1 | — |
| Thymic Stromal Lymphopoietin Blockers · MoA | 1 | — |
| Thymidine Phosphorylase Inhibitor · EPC | 1 | — |
| Thymidine Phosphorylase Inhibitors · MoA | 1 | — |
| Thyroid Hormone Receptor beta Agonist · EPC | 1 | — |
| Thyroid Hormone Receptor beta Agonists · MoA | 1 | — |
| Tissue Factor Pathway Inhibitor Antagonist · EPC | 1 | — |
| Tissue Factor Pathway Inhibitor Antagonists · MoA | 1 | — |
| Tissue-nonspecific Alkaline Phosphatase · EPC | 1 | — |
| Transthyretin-directed RNA Interaction · EPC | 1 | — |
| Tropomyosin Receptor Tyrosine Kinase A Inhibitors · MoA | 1 | — |
| Tropomyosin Receptor Tyrosine Kinase B Inhibitors · MoA | 1 | — |
| Tropomyosin Receptor Tyrosine Kinase C Inhibitors · MoA | 1 | — |
| Tryptophan Hydroxylase Inhibitor · EPC | 1 | — |
| Tryptophan Hydroxylase Inhibitors · MoA | 1 | — |
| Type I Interferon Receptor Antagonist · EPC | 1 | — |
| Type I Interferon Receptor Antagonists · MoA | 1 | — |
| UGT1A1 Inducers · MoA | 1 | — |
| Urate Oxidase · CS | 1 | — |
| Uric Acid-specific Enzyme · EPC | 1 | — |
| VEGFR2 Inhibitors · MoA | 1 | — |
| Vascular Endothelial Growth Factor Receptor 2 Antagonist · EPC | 1 | — |
| Vascular Sclerosing Activity · PE | 1 | — |
| Vinca Alkaloid · EPC | 1 | — |
| Vinca Alkaloids · CS | 1 | — |
| Vitamin B 6 [Chemical/Ingredient] · EPC | 1 | — |
| Vitamin B6 Analog · EPC | 1 | — |
| Vitamin C · EPC | 1 | — |
| Vitamin D · EPC | 1 | — |
| alpha-Glucosidases · CS | 1 | — |
| gamma-Aminobutyric Acid A Receptor Agonist · EPC | 1 | — |
| mu-Opioid Receptor Agonist · EPC | 1 | — |